Reported Consolidated quarterly numbers for Marksans Pharma are:Net Sales at Rs 348.96 crore in June 2021 up 5.38% from Rs. 331.15 crore in June 2020.
Quarterly Net Profit at Rs. 62.60 crore in June 2021 up 26.81% from Rs. 49.37 crore in June 2020.
EBITDA stands at Rs. 83.22 crore in June 2021 up 18.55% from Rs. 70.20 crore in June 2020.
Marksans Pharma EPS has increased to Rs. 1.51 in June 2021 from Rs. 1.20 in June 2020.
Marksans Pharma shares closed at 76.50 on August 10, 2021 (BSE) and has given 31.90% returns over the last 6 months and 57.89% over the last 12 months.
| Marksans Pharma | | Consolidated Quarterly Results | in Rs. Cr. |
|
| Jun'21 | Mar'21 | Jun'20 | | Net Sales/Income from operations | 348.96 | 330.20 | 331.15 | | Other Operating Income | -- | -- | -- | | Total Income From Operations | 348.96 | 330.20 | 331.15 | | EXPENDITURE | | Consumption of Raw Materials | 113.34 | 75.04 | 91.60 | | Purchase of Traded Goods | 6.33 | 148.72 | 43.46 | | Increase/Decrease in Stocks | 42.63 | -97.04 | 4.50 | | Power & Fuel | -- | -- | -- | | Employees Cost | 49.05 | 62.89 | 42.70 | | Depreciation | 7.47 | 1.33 | 7.25 | | Excise Duty | -- | -- | -- | | Admin. And Selling Expenses | -- | -- | -- | | R & D Expenses | -- | -- | -- | | Provisions And Contingencies | -- | -- | -- | | Exp. Capitalised | -- | -- | -- | | Other Expenses | 60.28 | 45.21 | 78.86 | | P/L Before Other Inc., Int., Excpt. Items & Tax | 69.87 | 94.04 | 62.77 | | Other Income | 5.88 | 6.01 | 0.18 | | P/L Before Int., Excpt. Items & Tax | 75.75 | 100.05 | 62.95 | | Interest | 0.97 | 2.83 | 1.55 | | P/L Before Exceptional Items & Tax | 74.78 | 97.22 | 61.40 | | Exceptional Items | -- | -- | -- | | P/L Before Tax | 74.78 | 97.22 | 61.40 | | Tax | 12.18 | 17.73 | 12.04 | | P/L After Tax from Ordinary Activities | 62.60 | 79.50 | 49.37 | | Prior Year Adjustments | -- | -- | -- | | Extra Ordinary Items | -- | -- | -- | | Net Profit/(Loss) For the Period | 62.60 | 79.50 | 49.37 | | Minority Interest | -- | -- | -- | | Share Of P/L Of Associates | -- | -- | -- | | Net P/L After M.I & Associates | 62.60 | 79.50 | 49.37 | | Equity Share Capital | 40.93 | 40.93 | 40.93 | | Reserves Excluding Revaluation Reserves | -- | -- | -- | | Equity Dividend Rate (%) | -- | -- | -- | | EPS Before Extra Ordinary | | Basic EPS | 1.51 | 1.93 | 1.20 | | Diluted EPS | 1.51 | 1.93 | 1.20 | | EPS After Extra Ordinary | | Basic EPS | 1.51 | 1.93 | 1.20 | | Diluted EPS | 1.51 | 1.93 | 1.20 | | Public Share Holding | | No Of Shares (Crores) | -- | -- | -- | | Share Holding (%) | -- | -- | -- | | Promoters and Promoter Group Shareholding | | a) Pledged/Encumbered | | - Number of shares (Crores) | -- | -- | -- | | - Per. of shares (as a % of the total sh. of prom. and promoter group) | -- | -- | -- | | - Per. of shares (as a % of the total Share Cap. of the company) | -- | -- | -- | | b) Non-encumbered | | - Number of shares (Crores) | -- | -- | -- | | - Per. of shares (as a % of the total sh. of prom. and promoter group) | -- | -- | -- | | - Per. of shares (as a % of the total Share Cap. of the company) | -- | -- | -- | | Source : Dion Global Solutions Limited |
|